{"filings":[{"id":92542,"accession_number":"0001384101-26-000029","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q1 2026 revenue $139.1M (+21% YoY); GAAP net income $28.7M, adj. EBITDA $42.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $139.1M (+21% YoY); testing revenue $135.1M (+26% YoY).","GAAP net income $28.7M (20.6% of revenue); adjusted EBITDA $42.8M (30.8% of revenue).","Decipher revenue $86.5M (+30%); Afirma revenue $46.4M (+21%).","Testing volume 45,248 (+19%); Decipher tests ~28,000 (+24%), Afirma ~17,200 (+12%).","Cash from operations $35.2M; cash & investments $439.1M; added Haas as CDTO and Ward as CHRO."],"consensus_eps_estimate":null,"consensus_eps_actual":0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":139071000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103449,"accession_number":"0001384101-26-000012","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Veracyte appoints Kevin Haas as Chief Development & Technology Officer, effective March 24, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kevin Haas, formerly CTO of Myriad Genetics (NASDAQ: MYGN), joins as Chief Development and Technology Officer.","Compensation includes $500,000 base salary, 55% target bonus, RSUs and PSUs each valued at $1.5 million.","RSU vests over four years; PSU vests upon achievement of performance objectives set by Compensation Committee.","No family relationships or material transactions with the company or its other officers disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103448,"accession_number":"0001384101-26-000008","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q4 revenue $140.6M (+19% YoY); GAAP net income $41.1M, generates $52.6M operating cash","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $140.6M (+19% YoY); testing revenue $135.8M (+21%); total volume 48,019 tests (+16%).","Decipher revenue $85.6M (+27%); Afirma revenue $47.9M (+16%); strong double-digit growth in both segments.","GAAP net income $41.1M (29.3% margin); adjusted EBITDA $42.3M (30.1% margin); $52.6M operating cash flow.","Full-year 2025 revenue $517.1M (+16% YoY); GAAP net income $66.4M; adjusted EBITDA $142.5M; operating cash $136.3M.","Ended 2025 with $412.9M cash; plans to launch Prosigna LDT and TrueMRD test in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":517145000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103447,"accession_number":"0001384101-26-000002","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte prelim Q4 rev $138M-$140M (+16-18% YoY); guides FY26 rev $570M-$582M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 total revenue $515M-$517M (+16% YoY); testing revenue $491M-$493M.","Decipher volume +27% to ~102K; Afirma volume +11% to ~67.7K in FY2025.","Prelim FY2025 adj EBITDA margin >25%; FY2026 margin guided at 25%.","FY2026 total revenue guidance 10-13% growth ($570M-$582M); testing rev +14-16% ($559M-$569M excl. new tests).","CEO cites upcoming US launch of Prosigna and TrueMRD as growth catalysts."],"consensus_eps_estimate":null,"consensus_eps_actual":0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":517145000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119703,"accession_number":"0001384101-25-000128","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q3 revenue up 14% to $131.9M, raises FY guidance; adjusted EBITDA margin 30%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $131.9M (+14% YoY); testing rev $127.8M (+17%); GAAP net income $19.1M.","Decipher revenue $82.2M (+26%); Afirma $43.2M (+7%); total testing volume +19% to 43,679.","Adjusted EBITDA $39.7M (30% margin); cash from ops $44.8M; cash & equivalents $366.4M.","Raised FY2025 total revenue guidance to $506-510M; testing rev guidance $484-487M (+16%).","Completed enrollment of Percepta Nasal Swab NIGHTINGALE trial; upcoming TrueMRD and Prosigna LDT launches."],"consensus_eps_estimate":null,"consensus_eps_actual":0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":376509000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136277,"accession_number":"0001384101-25-000106","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q2 revenue $130.2M (+14% YoY); raises testing revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue of $130.2M (+14% YoY); testing revenue of $122.3M (+14%).","Decipher revenue $76.3M (+24%), volume ~25,500 (+28%); Afirma revenue $43.4M (+5%).","GAAP net loss $1.0M includes $20.5M impairment; adj. EBITDA $35.8M (27.5% of revenue).","Cash from operations $33.6M; cash & investments $320.7M at quarter end.","Raises FY2025 testing revenue guidance to $477-483M (14-15% growth); FY total revenue $496-504M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":244637000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153379,"accession_number":"0001384101-25-000083","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"VCYT shareholders approve 2.5M share equity plan increase, elect all directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 2023 Plan Amendment to increase shares reserved by 2,500,000 (For: 50.6M, Against: 19.1M).","All seven director nominees elected; Muna Bhanji received 14% against votes (9.6M against, 545K abstain).","Advisory vote on executive compensation approved with 97.3% support (67.8M For, 1.8M Against).","Board adopts annual Say-on-Pay frequency based on advisory vote (66.8M for one year).","Ernst & Young ratified as independent auditor for 2025 with 99.7% approval (72.2M For)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153378,"accession_number":"0001384101-25-000058","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q1 2025 revenue $114.5M (+18% YoY); net income $7.0M, Decipher revenue up 33%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $114.5M (+18% YoY); testing revenue $107.3M (+19%); total test volume 40,655 (+22%).","Decipher revenue $66.6M (+33%); Afirma revenue $38.3M (+6%); Decipher volume ~22,600 (+37%).","Net income $7.0M (6.2% of revenue); adjusted EBITDA $24.7M (21.6% of revenue).","Launched limited access to Decipher for metastatic prostate cancer, expanding addressable population.","Cash and short-term investments $287.4M; generated $5.4M cash from ops."],"consensus_eps_estimate":null,"consensus_eps_actual":0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":114473000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172141,"accession_number":"0001384101-25-000010","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q4 revenue $118.6M (+21%), net income $5.1M vs. loss a year ago","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $118.6M (+21%), testing revenue $112.2M (+24%), testing volume +25% to 39,107 tests.","Q4 net income $5.1M vs. net loss in Q4 2023; adjusted EBITDA $26.1M (22.0% margin), up 76%.","Full-year 2024 revenue $445.8M (+23%), net income $24.1M vs. 2023 loss; adj. EBITDA $91.9M (20.6%).","Decipher revenue +44% in Q4, volume +45% to >22,400 tests; Afirma revenue +4%, volume +8%.","Cash from operations $75.1M in 2024; ended with $289.4M cash & short-term investments."],"consensus_eps_estimate":null,"consensus_eps_actual":0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":445764000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189109,"accession_number":"0001384101-24-000160","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q3 revenue $115.9M (+29% YoY), net income $15.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Testing revenue $109.5M (+34%); total testing volume 36,792 (+24%); total tests 39,032 (+20%).","Decipher revenue +48%, volume +36% (21,250 tests); Afirma revenue +19%, volume +12% (15,100 tests).","GAAP net income $15.2M; adjusted EBITDA $27.3M (24% margin); operating cash flow $30.0M.","Presented Decipher Prostate clinical data from STAMPEDE (ESMO) and VANDAAM (ASTRO); added two directors and SVP of Operations."],"consensus_eps_estimate":null,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":327132000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205597,"accession_number":"0001384101-24-000133","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Veracyte appoints Tom Miller, Ph.D. and Brent Shafer to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointments effective September 3, 2024; terms until 2025 annual meeting or successor.","Miller joins Regulatory and Compliance Committee; Shafer joins Compensation Committee.","Both eligible for standard non-employee director compensation; no related-party transactions.","No family relationships with existing directors or officers; standard indemnity agreements signed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205596,"accession_number":"0001384101-24-000116","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q2 revenue $114.4M (+27% YoY); net income $5.7M; record test volumes","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $114.4M (+27% YoY); testing revenue +31%; test volume 39,023 (+23%).","Net income $5.7M; adjusted EBITDA $24.0M (21% of revenue); generated $26.7M cash.","Record Decipher Prostate volume ~19,900 (NCCN guideline boost); Afirma volume ~15,700 (new Medicare coverage for Bethesda V).","Cash and cash equivalents $235.9M; three Decipher studies published including SEER-linked analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":211272000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222537,"accession_number":"0001384101-24-000093","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Veracyte stockholders approve 5M share increase under 2023 equity plan","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Annual meeting held June 12, 2024; all four proposals passed.","Stockholders approved amendment to 2023 Equity Incentive Plan adding 5,000,000 shares (45,241,870 For, 22,565,308 Against).","Directors Muna Bhanji (61,780,051 votes) and Marc Stapley (67,220,523) elected to one-year terms.","Ratified Ernst & Young as independent auditor for FY2024 (70,832,239 For).","Non-binding say-on-pay approved (64,610,097 For)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222536,"accession_number":"0001384101-24-000064","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q1 revenue $96.8M (+17%), testing revenue +25%, net loss narrows 77%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $96.8M (up 17% YoY); testing revenue $90.3M (up 25%) led by Decipher Prostate and Afirma.","Net loss improved 77% to $1.9M ($0.02 per share) from $8.3M loss in Q1 2023.","Non-GAAP gross margin held at 68%; non-GAAP op expenses grew 6% to $61.6M.","Decipher Prostate received highest NCCN rating; contracted with large commercial payer covering ~30M members.","Completed C2i Genomics acquisition for MRD testing; initiated bladder cancer MRD test; cash $209.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":96844000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222535,"accession_number":"0001384101-24-000051","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K/A","filed_at":"2024-04-17T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Veracyte completes C2i acquisition for up to $95M stock; C2i had $36M loss, $78.6M debt","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed Feb 5, 2024; total consideration up to $95M in Veracyte common stock.","C2i 2023 revenue $456k, net loss $36.0M, R&D expense $17.9M, operating loss $21.9M.","C2i had $78.6M in convertible promissory notes, $18.8M cash, $76.1M accumulated deficit as of Dec 31, 2023.","Veracyte files audited C2i financials and unaudited pro forma combined statements to satisfy SEC requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242060,"accession_number":"0001193125-24-075385","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Veracyte registers 1,016,965 shares for resale relating to C2i Genomics acquisition","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed prospectus supplement to register 1,016,965 shares of common stock for resale.","Shares were issued as part of the consideration for the February 5, 2024 acquisition of C2i Genomics.","Legal opinion from Fenwick & West LLP regarding the legality of the registered shares filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242059,"accession_number":"0001193125-24-053689","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Veracyte registers 1.68M shares for resale related to C2i Genomics acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement to register up to 1,681,384 shares of common stock for resale.","Shares were issued in connection with the acquisition of C2i Genomics, Inc. on Feb 5, 2024.","Includes opinion of counsel (Fenwick & West) on legality of the shares.","This is a procedural step; no new financial or operational information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242058,"accession_number":"0001384101-24-000013","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Veracyte Q4 revenue $98.2M (+22% YoY); full-year $361.1M (+22%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $98.2M, up 22% YoY; testing revenue $90.4M (+29%).","Full-year 2023 revenue $361.1M, up 22%; total test volume 126,977 (+24%).","Net loss $28.3M ($0.39/share) includes $32M impairment; non-GAAP gross margin 70%.","Generated $44M cash from operations in FY2023; cash on hand $216M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":361051000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242057,"accession_number":"0001384101-24-000007","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"John L. Bishop to retire from Veracyte board at 2024 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John L. Bishop informed the board he will retire and not stand for reelection at the 2024 annual meeting.","He will continue serving until the end of his term at the 2024 annual meeting.","Bishop has served on the board for ten years.","No replacement director has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242056,"accession_number":"0001384101-24-000004","cik":1384101,"company_name":"VERACYTE, INC.","ticker":"VCYT","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["2.01","9.01","3.02"],"status":"ready","headline":"Veracyte completes $70M acquisition of C2i Genomics; milestone payments up to $25M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price of $70M paid to C2i Genomics securityholders, subject to customary adjustments.","Up to $25M in additional milestone payments payable in cash or stock over next two years.","Veracyte to issue up to 2,698,349 shares as stock consideration; cash in lieu for non-accredited investors.","SEC granted partial waiver from certain financial statement requirements under Rule 3-13.","Closing occurred on February 5, 2024; audited C2i financials to be filed within 71 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3326560000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}